-
1
-
-
0035901090
-
Inflammation and cancer: Back to Virchow?
-
Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357(9255): 539-45.
-
(2001)
Lancet
, vol.357
, Issue.9255
, pp. 539-545
-
-
Balkwill, F.1
Mantovani, A.2
-
2
-
-
0022891340
-
Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing
-
Dvorak HF. Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315(26): 1650-9.
-
(1986)
N Engl J Med
, vol.315
, Issue.26
, pp. 1650-1659
-
-
Dvorak, H.F.1
-
3
-
-
84862278783
-
T cells in gastric cancer: Friends or foes
-
Amedei A, Della Bella C, Silvestri E, Prisco D, D'Elios MM. T cells in gastric cancer: Friends or foes. Clin Dev Immunol 2012; 2012: 690571.
-
(2012)
Clin Dev Immunol
, vol.2012
, pp. 690571
-
-
Amedei, A.1
Della Bella, C.2
Silvestri, E.3
Prisco, D.4
D'Elios, M.M.5
-
4
-
-
84857141296
-
Cancer-related inflammation: Common themes and therapeutic opportunities
-
Balkwill FR, Mantovani A. Cancer-related inflammation: Common themes and therapeutic opportunities. Semin Cancer Biol 2012; 22(1): 33-40.
-
(2012)
Semin Cancer Biol
, vol.22
, Issue.1
, pp. 33-40
-
-
Balkwill, F.R.1
Mantovani, A.2
-
5
-
-
79956191029
-
Chronic inflammation and cancer: The role of the mitochondria
-
Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: The role of the mitochondria. Oncology (Williston Park) 2011; 25(5): 400-10.
-
(2011)
Oncology (Williston Park)
, vol.25
, Issue.5
, pp. 400-410
-
-
Kamp, D.W.1
Shacter, E.2
Weitzman, S.A.3
-
6
-
-
84875354135
-
Chemokines in tumor development and progression
-
Mukaida N, Baba T. Chemokines in tumor development and progression. Exp Cell Res 2012; 317(5): 664-73.
-
(2012)
Exp Cell Res
, vol.317
, Issue.5
, pp. 664-673
-
-
Mukaida, N.1
Baba, T.2
-
7
-
-
42549172436
-
Interfering with chemokines and chemokine receptors as potential new therapeutic strategies
-
D'Elios MM, Del Prete G, Amedei A. Interfering with chemokines and chemokine receptors as potential new therapeutic strategies. Expert Opin Ther Pat 2008; 18(3): 309-25.
-
(2008)
Expert Opin Ther Pat
, vol.18
, Issue.3
, pp. 309-325
-
-
D'Elios, M.M.1
Del Prete, G.2
Amedei, A.3
-
8
-
-
34848855567
-
Less yin, more yang: Confronting the barriers to cancer immunotherapy
-
Lizée G, Cantu MA, Hwu P. Less yin, more yang: Confronting the barriers to cancer immunotherapy. Clin Cancer Res 2007; 13(18 Pt 1): 5250-5.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.18 PART 1
, pp. 5250-5255
-
-
Lizée, G.1
Cantu, M.A.2
Hwu, P.3
-
9
-
-
53549087527
-
How tumours escape mass destruction
-
Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008; 27(45): 5894-903.
-
(2008)
Oncogene
, vol.27
, Issue.45
, pp. 5894-5903
-
-
Stewart, T.J.1
Abrams, S.I.2
-
10
-
-
0036852241
-
Cancer immunoediting: From immunosurveillance to tumor escape
-
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3(11): 991-8.
-
(2002)
Nat Immunol
, vol.3
, Issue.11
, pp. 991-998
-
-
Dunn, G.P.1
Bruce, A.T.2
Ikeda, H.3
Old, L.J.4
Schreiber, R.D.5
-
11
-
-
67649305234
-
New frontiers in cell-based immunotherapy of cancer
-
D'Elios MM, Del Prete G, Amedei A. New frontiers in cell-based immunotherapy of cancer. Expert Opin Ther Pat 2009; 19(5): 623-41.
-
(2009)
Expert Opin Ther Pat
, vol.19
, Issue.5
, pp. 623-641
-
-
D'Elios, M.M.1
Del Prete, G.2
Amedei, A.3
-
12
-
-
0020288361
-
Interferon increases HLA synthesis in melanoma cells: Interferon-resistant and-sensitive cell lines
-
Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: Interferon-resistant and-sensitive cell lines. Proc Natl Acad Sci USA 1982; 79(10): 3265-9.
-
(1982)
Proc Natl Acad Sci USA
, vol.79
, Issue.10
, pp. 3265-3269
-
-
Basham, T.Y.1
Bourgeade, M.F.2
Creasey, A.A.3
Merigan, T.C.4
-
13
-
-
61849134433
-
Addition of interferon-alpha to a standard maturation cocktail induces CD38 upregulation and increases dendritic cell function
-
Trepiakas R, Pedersen AE, Met O, Svane IM. Addition of interferon-alpha to a standard maturation cocktail induces CD38 upregulation and increases dendritic cell function. Vaccine 2009; 27(16): 2213-19.
-
(2009)
Vaccine
, vol.27
, Issue.16
, pp. 2213-2219
-
-
Trepiakas, R.1
Pedersen, A.E.2
Met, O.3
Svane, I.M.4
-
14
-
-
0033546053
-
The nature of the principal type 1 interferonproducing cells in human blood
-
Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferonproducing cells in human blood. Science 1999; 284(5421): 1835-7.
-
(1999)
Science
, vol.284
, Issue.5421
, pp. 1835-1837
-
-
Siegal, F.P.1
Kadowaki, N.2
Shodell, M.3
Fitzgerald-Bocarsly, P.A.4
Shah, K.5
Ho, S.6
-
15
-
-
22144465860
-
A critical function for type I interferons in cancer immunoediting
-
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6(7): 722-9.
-
(2005)
Nat Immunol
, vol.6
, Issue.7
, pp. 722-729
-
-
Dunn, G.P.1
Bruce, A.T.2
Sheehan, K.C.3
Shankaran, V.4
Uppaluri, R.5
Bui, J.D.6
-
16
-
-
34547099363
-
The interferons: 50 years after their discovery, there is much more to learn
-
Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282(28): 20047-51.
-
(2007)
J Biol Chem
, vol.282
, Issue.28
, pp. 20047-20051
-
-
Pestka, S.1
-
17
-
-
0037790592
-
Apoptosis and interferons: Role of interferonstimulated genes as mediators of apoptosis
-
Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, et al. Apoptosis and interferons: Role of interferonstimulated genes as mediators of apoptosis. Apoptosis 2003; 8(3): 237-49.
-
(2003)
Apoptosis
, vol.8
, Issue.3
, pp. 237-249
-
-
Chawla-Sarkar, M.1
Lindner, D.J.2
Liu, Y.F.3
Williams, B.R.4
Sen, G.C.5
Silverman, R.H.6
-
18
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4(6): 423-36.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.6
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
19
-
-
0034088027
-
High-and low-dose interferon alfa-2b in highrisk melanoma: First analysis of intergroup trial e1690/s9111/c9190
-
Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in highrisk melanoma: First analysis of intergroup trial e1690/s9111/c9190. J Clin Oncol 2000; 18(12): 2444-58.
-
(2000)
J Clin Oncol
, vol.18
, Issue.12
, pp. 2444-2458
-
-
Kirkwood, J.M.1
Ibrahim, J.G.2
Sondak, V.K.3
Richards, J.4
Flaherty, L.E.5
Ernstoff, M.S.6
-
20
-
-
1842533233
-
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
-
Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10(5): 1670-7.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.5
, pp. 1670-1677
-
-
Kirkwood, J.M.1
Manola, J.2
Ibrahim, J.3
Sondak, V.4
Ernstoff, M.S.5
Rao, U.6
-
21
-
-
0030030347
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684. J Clin Oncol 1996; 14(1): 7-17.
-
(1996)
J Clin Oncol
, vol.14
, Issue.1
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
Smith, T.J.4
Borden, E.C.5
Blum, R.H.6
-
22
-
-
77950576363
-
Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis
-
Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Nat Cancer Inst 2010; 102(7): 493-501.
-
(2010)
J Nat Cancer Inst
, vol.102
, Issue.7
, pp. 493-501
-
-
Mocellin, S.1
Pasquali, S.2
Rossi, C.R.3
Nitti, D.4
-
23
-
-
0022500725
-
Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients
-
Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, et al. Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients. J Clin Oncol 1986; 4(6): 900-5.
-
(1986)
J Clin Oncol
, vol.4
, Issue.6
, pp. 900-905
-
-
Golomb, H.M.1
Jacobs, A.2
Fefer, A.3
Ozer, H.4
Thompson, J.5
Portlock, C.6
-
24
-
-
0022914303
-
Alpha interferons in B-cell neoplasms
-
Quesada JR, Gutterman JU. Alpha interferons in B-cell neoplasms. Br J Haematol 1986; 64(4): 639-46.
-
(1986)
Br J Haematol
, vol.64
, Issue.4
, pp. 639-646
-
-
Quesada, J.R.1
Gutterman, J.U.2
-
25
-
-
0037362951
-
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine
-
Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21(5): 891-6.
-
(2003)
J Clin Oncol
, vol.21
, Issue.5
, pp. 891-896
-
-
Goodman, G.R.1
Burian, C.2
Koziol, J.A.3
Saven, A.4
-
26
-
-
79959293462
-
Braf mutations in hairy-cell leukemia
-
Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. Braf mutations in hairy-cell leukemia. N Engl J Med 2011; 364(24): 2305-15.
-
(2011)
N Engl J Med
, vol.364
, Issue.24
, pp. 2305-2315
-
-
Tiacci, E.1
Trifonov, V.2
Schiavoni, G.3
Holmes, A.4
Kern, W.5
Martelli, M.P.6
-
27
-
-
77954373338
-
Selective brafv600e inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
-
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective brafv600e inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70(13): 5213-9.
-
(2010)
Cancer Res
, vol.70
, Issue.13
, pp. 5213-5219
-
-
Boni, A.1
Cogdill, A.P.2
Dang, P.3
Udayakumar, D.4
Njauw, C.N.5
Sloss, C.M.6
-
32
-
-
4344710617
-
Regulation of gene expression by pegylated IFN-alpha2B and IFN-alpha2B in human peripheral blood mononuclear cells
-
Brassard DL, Delorenzo MM, Cox S, Leaman DW, Sun Y, Ding W, et al. Regulation of gene expression by pegylated IFN-alpha2B and IFN-alpha2B in human peripheral blood mononuclear cells. J Interferon Cytokine Res 2004; 24(8): 455-69.
-
(2004)
J Interferon Cytokine Res
, vol.24
, Issue.8
, pp. 455-469
-
-
Brassard, D.L.1
Delorenzo, M.M.2
Cox, S.3
Leaman, D.W.4
Sun, Y.5
Ding, W.6
-
33
-
-
67649933805
-
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
-
Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27(18): 2916-23.
-
(2009)
J Clin Oncol
, vol.27
, Issue.18
, pp. 2916-2923
-
-
Bottomley, A.1
Coens, C.2
Suciu, S.3
Santinami, M.4
Kruit, W.5
Testori, A.6
-
34
-
-
84855982908
-
Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: Patients' and doctors' views
-
Loquai C, Schmidtmann I, Beutel M, Sunderkötter C, Grabbe S, Schiller M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: Patients' and doctors' views. Eur J Dermatol 2011; 21(6): 976-84.
-
(2011)
Eur J Dermatol
, vol.21
, Issue.6
, pp. 976-984
-
-
Loquai, C.1
Schmidtmann, I.2
Beutel, M.3
Sunderkötter, C.4
Grabbe, S.5
Schiller, M.6
-
35
-
-
0036019503
-
Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner
-
Satomi H, Wang B, Fujisawa H, Otsuka F. Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. Cytokine 2002; 18(2): 108-15.
-
(2002)
Cytokine
, vol.18
, Issue.2
, pp. 108-115
-
-
Satomi, H.1
Wang, B.2
Fujisawa, H.3
Otsuka, F.4
-
36
-
-
0020377792
-
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells
-
Borden EC, Hogan TF, Voelkel JG. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res 1982; 42(12): 4948-53.
-
(1982)
Cancer Res
, vol.42
, Issue.12
, pp. 4948-4953
-
-
Borden, E.C.1
Hogan, T.F.2
Voelkel, J.G.3
-
37
-
-
0034895641
-
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2l induction in melanoma cell lines
-
Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2l induction in melanoma cell lines. Clin Cancer Res 2001; 7(6): 1821-31.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.6
, pp. 1821-1831
-
-
Chawla-Sarkar, M.1
Leaman, D.W.2
Borden, E.C.3
-
39
-
-
0023197097
-
Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production
-
Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236(4804): 944-47.
-
(1987)
Science
, vol.236
, Issue.4804
, pp. 944-947
-
-
Snapper, C.M.1
Paul, W.E.2
-
40
-
-
22144465860
-
A critical function for type I interferons in cancer immunoediting
-
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6(8): 722-9.
-
(2005)
Nat Immunol
, vol.6
, Issue.8
, pp. 722-729
-
-
Dunn, G.P.1
Bruce, A.T.2
Sheehan, K.C.3
Shankaran, V.4
Uppaluri, R.5
Bui, J.D.6
-
41
-
-
0036645530
-
Suppression of lymphoma and epithelial malignancies effected by interferon gamma
-
Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196(1): 129-34.
-
(2002)
J Exp Med
, vol.196
, Issue.1
, pp. 129-134
-
-
Street, S.E.1
Trapani, J.A.2
McGregor, D.3
Smyth, M.J.4
-
42
-
-
17344383269
-
Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
-
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, et al. Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9(1): 25-34.
-
(1998)
Immunity
, vol.9
, Issue.1
, pp. 25-34
-
-
Coughlin, C.M.1
Salhany, K.E.2
Gee, M.S.3
LaTemple, D.C.4
Kotenko, S.5
Ma, X.6
-
43
-
-
0023118633
-
Inhibition of endothelial cell proliferation by gamma-interferon
-
Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104(3): 689-96.
-
(1987)
J Cell Biol
, vol.104
, Issue.3
, pp. 689-696
-
-
Friesel, R.1
Komoriya, A.2
McIag, T.3
-
44
-
-
0033775561
-
Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian urologic oncology group
-
Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian urologic oncology group. BJU Int 2000; 86(6): 613-8.
-
(2000)
BJU Int
, vol.86
, Issue.6
, pp. 613-618
-
-
Elhilali, M.M.1
Gleave, M.2
Fradet, Y.3
Davis, I.4
Venner, P.5
Saad, F.6
-
45
-
-
0036375296
-
Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation
-
Koziner B, Dengra C, Cisneros M, Glancszpigel R. Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation. Acta Haematol 2002; 108(2): 66-73.
-
(2002)
Acta Haematol
, vol.108
, Issue.2
, pp. 66-73
-
-
Koziner, B.1
Dengra, C.2
Cisneros, M.3
Glancszpigel, R.4
-
46
-
-
0037232131
-
Novel interferons
-
Vilcek, J. Novel interferons. Nat Immunol 2003; 4(1): 8-9.
-
(2003)
Nat Immunol
, vol.4
, Issue.1
, pp. 8-9
-
-
Vilcek, J.1
-
48
-
-
77955886364
-
Interferon-lambda as a potential therapeutic agent in cancer treatment
-
Steen HC, Gamero AM. Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010; 30(8): 597-602.
-
(2010)
J Interferon Cytokine Res
, vol.30
, Issue.8
, pp. 597-602
-
-
Steen, H.C.1
Gamero, A.M.2
-
50
-
-
0024391574
-
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation
-
Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 1989; 29(4): 261-9.
-
(1989)
Cancer Immunol Immunother
, vol.29
, Issue.4
, pp. 261-269
-
-
Voss, S.D.1
Hank, J.A.2
Nobis, C.A.3
Fisch, P.4
Sosman, J.A.5
Sondel, P.M.6
-
51
-
-
0034716925
-
Regulatory t cells: Key controllers of immunologic self-tolerance
-
Sakaguchi S. Regulatory t cells: Key controllers of immunologic self-tolerance. Cell 2000; 101(5): 455.
-
(2000)
Cell
, vol.101
, Issue.5
, pp. 455
-
-
Sakaguchi, S.1
-
54
-
-
0036276002
-
Interleukin-2: Clinical applications
-
Atkins MB. Interleukin-2: Clinical applications. Semin Oncol 2002; 29(3 Suppl 7): 12-17.
-
(2002)
Semin Oncol
, vol.29
, Issue.3 SUPPL. 7
, pp. 12-17
-
-
Atkins, M.B.1
-
55
-
-
0033847587
-
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
-
Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl 1): S55-S7.
-
(2000)
Cancer J Sci Am
, vol.6
, Issue.SUPPL. 1
-
-
Fisher, R.I.1
Rosenberg, S.A.2
Fyfe, G.3
-
56
-
-
0028060152
-
A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice
-
Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91(20): 9626-30.
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, Issue.20
, pp. 9626-9630
-
-
Sabzevari, H.1
Gillies, S.D.2
Mueller, B.M.3
Pancook, J.D.4
Reisfeld, R.A.5
-
57
-
-
0034896595
-
Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy
-
Christ O, Seiter S, Matzku S, Burger C, Zöller M. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. Clin Cancer Res 2001; 7(4): 985-98.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.4
, pp. 985-998
-
-
Christ, O.1
Seiter, S.2
Matzku, S.3
Burger, C.4
Zöller, M.5
-
58
-
-
52549117059
-
Intratumoral immunocytokine treatment results in enhanced antitumor effects
-
Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, et al. Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 2008; 57(12): 1891-902.
-
(2008)
Cancer Immunol Immunother
, vol.57
, Issue.12
, pp. 1891-1902
-
-
Johnson, E.E.1
Lum, H.D.2
Rakhmilevich, A.L.3
Schmidt, B.E.4
Furlong, M.5
Buhtoiarov, I.N.6
-
59
-
-
70349439274
-
Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma
-
Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, et al. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res 2009; 15(18): 5923-30.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.18
, pp. 5923-5930
-
-
Hank, J.A.1
Gan, J.2
Ryu, H.3
Ostendorf, A.4
Stauder, M.C.5
Sternberg, A.6
-
60
-
-
67650442052
-
The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
-
Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 2009; 18(7): 991-1000.
-
(2009)
Expert Opin Investig Drugs
, vol.18
, Issue.7
, pp. 991-1000
-
-
Yamane, B.H.1
Hank, J.A.2
Albertini, M.R.3
Sondel, P.M.4
-
61
-
-
0031740732
-
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency
-
Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20(4): 394-39.
-
(1998)
Nat Genet
, vol.20
, Issue.4
, pp. 339-394
-
-
Puel, A.1
Ziegler, S.F.2
Buckley, R.H.3
Leonard, W.J.4
-
62
-
-
0034332403
-
Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo
-
Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1(5): 426-32.
-
(2000)
Nat Immunol
, vol.1
, Issue.5
, pp. 426-432
-
-
Schluns, K.S.1
Kieper, W.C.2
Jameson, S.C.3
Lefrançois, L.4
-
65
-
-
69249230925
-
+ T-cell responses after immunization with recombinant lentivector
-
+ T-cell responses after immunization with recombinant lentivector. Blood 2009; 113(26): 6629-37.
-
(2009)
Blood
, vol.113
, Issue.26
, pp. 6629-6637
-
-
Colombetti, S.1
Lévy, F.2
Chapatte, L.3
-
66
-
-
79955418828
-
Harnessing the biology of IL-7 for therapeutic application
-
Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11(5): 330-42.
-
(2011)
Nat Rev Immunol
, vol.11
, Issue.5
, pp. 330-342
-
-
McKall, C.L.1
Fry, T.J.2
Gress, R.E.3
-
68
-
-
84055199517
-
Cytokines in cancer immunotherapy
-
Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers 2011; 3: 3856-93.
-
(2011)
Cancers
, vol.3
, pp. 3856-3893
-
-
Lee, S.1
Margolin, K.2
-
69
-
-
33646580769
-
The structure of the interleukin-15 alpha receptor and its implications for ligand binding
-
Lorenzen I, Dingley AJ, Jacques Y, Grötzinger J. The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem 2006; 281(10): 6642-7.
-
(2006)
J Biol Chem
, vol.281
, Issue.10
, pp. 6642-6647
-
-
Lorenzen, I.1
Dingley, A.J.2
Jacques, Y.3
Grötzinger, J.4
-
70
-
-
0034633683
-
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
-
Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 2000; 97(21): 11445-50.
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.21
, pp. 11445-11450
-
-
Marks-Konczalik, J.1
Dubois, S.2
Losi, J.M.3
Sabzevari, H.4
Yamada, N.5
Feigenbaum, L.6
-
72
-
-
0034665093
-
The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement
-
Di Carlo E, Comes A, Basso S, De Ambrosis A, Meazza R, Musiani P, et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 2000; 165(6): 3111-8.
-
(2000)
J Immunol
, vol.165
, Issue.6
, pp. 3111-3118
-
-
Di Carlo, E.1
Comes, A.2
Basso, S.3
de Ambrosis, A.4
Meazza, R.5
Musiani, P.6
-
73
-
-
4444240035
-
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokineactivated killer cells in celiac disease
-
Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokineactivated killer cells in celiac disease. Immunity 2004; 21(3): 357-66.
-
(2004)
Immunity
, vol.21
, Issue.3
, pp. 357-366
-
-
Meresse, B.1
Chen, Z.2
Ciszewski, C.3
Tretiakova, M.4
Bhagat, G.5
Krausz, T.N.6
-
74
-
-
0346995205
-
IL-21: A novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses
-
Habib T, Nelson A, Kaushansky K. IL-21: A novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 2003; 112(6): 1033-45.
-
(2003)
J Allergy Clin Immunol
, vol.112
, Issue.6
, pp. 1033-1045
-
-
Habib, T.1
Nelson, A.2
Kaushansky, K.3
-
75
-
-
2542565699
-
Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated antitumour responses
-
Sivakumar PV, Foster DC, Clegg CH. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated antitumour responses. Immunology 2004; 112(2): 177-82.
-
(2004)
Immunology
, vol.112
, Issue.2
, pp. 177-182
-
-
Sivakumar, P.V.1
Foster, D.C.2
Clegg, C.H.3
-
77
-
-
33746088835
-
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
-
He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006; 4: 24.
-
(2006)
J Transl Med
, vol.4
, pp. 24
-
-
He, H.1
Wisner, P.2
Yang, G.3
Hu, H.M.4
Haley, D.5
Miller, W.6
-
78
-
-
33745139171
-
Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma
-
Curti BD. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev Anticancer Ther 2006; 6(6): 905-9.
-
(2006)
Expert Rev Anticancer Ther
, vol.6
, Issue.6
, pp. 905-909
-
-
Curti, B.D.1
-
79
-
-
0347320749
-
In vivo antitumor activity of interleukin 21 mediated by natural killer cells
-
Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63(24): 9016-22.
-
(2003)
Cancer Res
, vol.63
, Issue.24
, pp. 9016-9022
-
-
Wang, G.1
Tschoi, M.2
Spolski, R.3
Lou, Y.4
Ozaki, K.5
Feng, C.6
-
80
-
-
10744230081
-
Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma
-
Kishida T, Asada H, Itokawa Y, Cui FD, Shin-Ya M, Gojo S, et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 2003; 8(4): 552-8.
-
(2003)
Mol Ther
, vol.8
, Issue.4
, pp. 552-558
-
-
Kishida, T.1
Asada, H.2
Itokawa, Y.3
Cui, F.D.4
Shin-Ya, M.5
Gojo, S.6
-
81
-
-
23444445913
-
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response
-
Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005; 175(4): 2261-9.
-
(2005)
J Immunol
, vol.175
, Issue.4
, pp. 2261-2269
-
-
Li, Y.1
Bleakley, M.2
Yee, C.3
-
82
-
-
0142250392
-
Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence
-
Trikha M, Corringham R, Klein B, Rossi JF. Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003; 9(13): 4653-65.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.13
, pp. 4653-4665
-
-
Trikha, M.1
Corringham, R.2
Klein, B.3
Rossi, J.F.4
-
83
-
-
0031811798
-
Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study
-
van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. Brit J Haematol 1998; 102(3): 783-90.
-
(1998)
Brit J Haematol
, vol.102
, Issue.3
, pp. 783-790
-
-
van Zaanen, H.C.1
Lokhorst, H.M.2
Aarden, L.A.3
Rensink, H.J.4
Warnaar, S.O.5
van der Lelie, J.6
-
84
-
-
0030796001
-
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
-
Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72(3): 424-30.
-
(1997)
Int J Cancer
, vol.72
, Issue.3
, pp. 424-430
-
-
Blay, J.Y.1
Rossi, J.F.2
Wijdenes, J.3
Menetrier-Caux, C.4
Schemann, S.5
Négrier, S.6
-
85
-
-
0026591094
-
Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients
-
Chehimi J, Starr SE, Frank I, Rengaraju M, Jackson SJ, Llanes C, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175(3): 789-96.
-
(1992)
J Exp Med
, vol.175
, Issue.3
, pp. 789-796
-
-
Chehimi, J.1
Starr, S.E.2
Frank, I.3
Rengaraju, M.4
Jackson, S.J.5
Llanes, C.6
-
86
-
-
13444249480
-
Synergistic effects of IL-12 and IL-18 in skewing tumorreactive T-cell responses towards a type 1 pattern
-
Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, et al. Synergistic effects of IL-12 and IL-18 in skewing tumorreactive T-cell responses towards a type 1 pattern. Cancer Res 2005; 65(3): 1063-70.
-
(2005)
Cancer Res
, vol.65
, Issue.3
, pp. 1063-1070
-
-
Li, Q.1
Carr, A.L.2
Donald, E.J.3
Skitzki, J.J.4
Okuyama, R.5
Stoolman, L.M.6
-
87
-
-
0037086632
-
Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity
-
Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002; 20(13-14): 1862-9.
-
(2002)
Vaccine
, vol.20
, Issue.13-14
, pp. 1862-1869
-
-
Kaufman, H.L.1
Flanagan, K.2
Lee, C.S.3
Perretta, D.J.4
Horig, H.5
-
88
-
-
0031637367
-
Critical role of NK1+ T cells in IL-12-induced immune responses in vivo
-
Kawamura T, Takeda K, Mendiratta SK, Kawamura H, Van Kaer L, Yagita H, et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 1998; 160(1): 16-9.
-
(1998)
J Immunol
, vol.160
, Issue.1
, pp. 16-19
-
-
Kawamura, T.1
Takeda, K.2
Mendiratta, S.K.3
Kawamura, H.4
van Kaer, L.5
Yagita, H.6
-
89
-
-
0034103809
-
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
-
Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6(5): 1678-92.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.5
, pp. 1678-1692
-
-
Gollob, J.A.1
Mier, J.W.2
Veenstra, K.3
McDermott, D.F.4
Clancy, D.5
Clancy, M.6
-
90
-
-
58049200809
-
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
-
Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26(36): 5896-903.
-
(2008)
J Clin Oncol
, vol.26
, Issue.36
, pp. 5896-5903
-
-
Daud, A.I.1
DeConti, R.C.2
Andrews, S.3
Urbas, P.4
Riker, A.I.5
Sondak, V.K.6
-
91
-
-
15444347156
-
A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3-cells
-
Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H, et al. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3-cells. J Immunol 1998; 160(10): 4738-46.
-
(1998)
J Immunol
, vol.160
, Issue.10
, pp. 4738-4746
-
-
Tomura, M.1
Zhou, X.Y.2
Maruo, S.3
Ahn, H.J.4
Hamaoka, T.5
Okamura, H.6
-
93
-
-
0031860165
-
Regulation of interferon-gamma production by IL-12 and IL-18
-
Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998; 10(3): 259-64.
-
(1998)
Curr Opin Immunol
, vol.10
, Issue.3
, pp. 259-264
-
-
Okamura, H.1
Kashiwamura, S.2
Tsutsui, H.3
Yoshimoto, T.4
Nakanishi, K.5
-
94
-
-
0035424134
-
Evidence of IL-18 as a novel angiogenic mediator
-
Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001; 167(3): 1644-53.
-
(2001)
J Immunol
, vol.167
, Issue.3
, pp. 1644-1653
-
-
Park, C.C.1
Morel, J.C.2
Amin, M.A.3
Connors, M.A.4
Harlow, L.A.5
Koch, A.E.6
-
95
-
-
2942588523
-
Differences in signaling pathways by IL-1beta and IL-18
-
Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1beta and IL-18. Proc Natl Acad Sci USA 2004; 101(23): 8815-20.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, Issue.23
, pp. 8815-8820
-
-
Lee, J.K.1
Kim, S.H.2
Lewis, E.C.3
Azam, T.4
Reznikov, L.L.5
Dinarello, C.A.6
-
96
-
-
84875299700
-
-
EP2338514
-
Haskova, Z., Jonak, Z.L., Trulli, S., Whitacre, M. Combined human IL-18 and pazopanib cancer treatment. EP2338514 (2011).
-
(2011)
Combined human IL-18 and pazopanib cancer treatment
-
-
Haskova, Z.1
Jonak, Z.L.2
Trulli, S.3
Whitacre, M.4
-
97
-
-
0141956433
-
Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF
-
Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003; 112(4): 653-65.
-
(2003)
J Allergy Clin Immunol
, vol.112
, Issue.4
, pp. 653-665
-
-
Martinez-Moczygemba, M.1
Huston, D.P.2
-
98
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
-
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90(8): 3539-43.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, Issue.8
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
Golumbek, P.4
Levitsky, H.5
Brose, K.6
-
99
-
-
0037076319
-
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction
-
Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci USA 2002; 99(10): 6919-24.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, Issue.10
, pp. 6919-6924
-
-
Hodi, F.S.1
Schmollinger, J.C.2
Soiffer, R.J.3
Salgia, R.4
Lynch, T.5
Ritz, J.6
-
100
-
-
0032809320
-
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
-
Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5(7): 1738-44.
-
(1999)
Clin Cancer Res
, vol.5
, Issue.7
, pp. 1738-1744
-
-
Small, E.J.1
Reese, D.M.2
Um, B.3
Whisenant, S.4
Dixon, S.C.5
Figg, W.D.6
-
101
-
-
0022478367
-
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
-
Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232(4749): 506-8.
-
(1986)
Science
, vol.232
, Issue.4749
, pp. 506-508
-
-
Grabstein, K.H.1
Urdal, D.L.2
Tushinski, R.J.3
Mochizuki, D.Y.4
Price, V.L.5
Cantrell, M.A.6
-
102
-
-
51949103823
-
Serum lipids regulate dendritic cell CD1 expression and function
-
Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC, et al. Serum lipids regulate dendritic cell CD1 expression and function. Immunology 2008; 125(3): 289-301.
-
(2008)
Immunology
, vol.125
, Issue.3
, pp. 289-301
-
-
Leslie, D.S.1
Dascher, C.C.2
Cembrola, K.3
Townes, M.A.4
Hava, D.L.5
Hugendubler, L.C.6
-
103
-
-
34447121852
-
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and antiinflammatory activities of GMCSF
-
Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and antiinflammatory activities of GMCSF. J Clin Invest 2007; 117(7): 1902-13.
-
(2007)
J Clin Invest
, vol.117
, Issue.7
, pp. 1902-1913
-
-
Jinushi, M.1
Nakazaki, Y.2
Dougan, M.3
Carrasco, D.R.4
Mihm, M.5
Dranoff, G.6
-
104
-
-
0034807621
-
Intralesional granulocyte-monocyte colonystimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients
-
Ridolfi L, Ridolfi R, Ascari-Raccagni A, Fabbri M, Casadei S, Gatti A, et al. Intralesional granulocyte-monocyte colonystimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001; 15(3): 218-23.
-
(2001)
J Eur Acad Dermatol Venereol
, vol.15
, Issue.3
, pp. 218-223
-
-
Ridolfi, L.1
Ridolfi, R.2
Ascari-Raccagni, A.3
Fabbri, M.4
Casadei, S.5
Gatti, A.6
-
105
-
-
0038793763
-
GM-CSF-secreting melanoma vaccines
-
Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22(20): 3188-92.
-
(2003)
Oncogene
, vol.22
, Issue.20
, pp. 3188-3192
-
-
Dranoff, G.1
-
106
-
-
33845336115
-
A phase I study of OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
-
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12(22): 6737-47.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.22
, pp. 6737-6747
-
-
Hu, J.C.1
Coffin, R.S.2
Davis, C.J.3
Graham, N.J.4
Groves, N.5
Guest, P.J.6
-
107
-
-
73349133717
-
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma
-
Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27(34): 5763-71.
-
(2009)
J Clin Oncol
, vol.27
, Issue.34
, pp. 5763-5771
-
-
Senzer, N.N.1
Kaufman, H.L.2
Amatruda, T.3
Nemunaitis, M.4
Reid, T.5
Daniels, G.6
-
108
-
-
77149141965
-
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
-
Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17(3): 718-30.
-
(2010)
Ann Surg Oncol
, vol.17
, Issue.3
, pp. 718-730
-
-
Kaufman, H.L.1
Kim, D.W.2
DeRaffele, G.3
Mitcham, J.4
Coffin, R.S.5
Kim-Schulze, S.6
-
109
-
-
77957253429
-
Optim trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
-
Kaufman HL, Bines SD. Optim trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6(6): 941-9.
-
(2010)
Future Oncol
, vol.6
, Issue.6
, pp. 941-949
-
-
Kaufman, H.L.1
Bines, S.D.2
-
111
-
-
41149108216
-
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
-
Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008; 222: 287-98.
-
(2008)
Immunol Rev
, vol.222
, pp. 287-298
-
-
Jinushi, M.1
Hodi, F.S.2
Dranoff, G.3
-
112
-
-
0141576738
-
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
-
Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21(17): 3343-50.
-
(2003)
J Clin Oncol
, vol.21
, Issue.17
, pp. 3343-3350
-
-
Soiffer, R.1
Hodi, F.S.2
Haluska, F.3
Jung, K.4
Gillessen, S.5
Singer, S.6
-
113
-
-
0642311904
-
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells
-
Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21(21): 4016-26.
-
(2003)
J Clin Oncol
, vol.21
, Issue.21
, pp. 4016-4026
-
-
Slingluff Jr., C.L.1
Petroni, G.R.2
Yamshchikov, G.V.3
Barnd, D.L.4
Eastham, S.5
Galavotti, H.6
-
114
-
-
84875353958
-
-
WO2011079077
-
Nemunaitis, J., Senzer, N., Maples, P.B., Rao, D. Furin-knockdown and GM-CSF-augmented (Fang) cancer vaccine. WO2011079077 (2011).
-
(2011)
Furin-knockdown and GM-CSF-augmented (Fang) cancer vaccine
-
-
Nemunaitis, J.1
Senzer, N.2
Maples, P.B.3
Rao, D.4
-
116
-
-
0034080318
-
The biology of chemokines and their receptors
-
Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
-
(2000)
Annu Rev Immunol
, vol.18
, pp. 217-242
-
-
Rossi, D.1
Zlotnik, A.2
-
117
-
-
0034829818
-
Chemokines in pathology and medicine
-
Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250(2): 91-104.
-
(2001)
J Intern Med
, vol.250
, Issue.2
, pp. 91-104
-
-
Baggiolini, M.1
-
118
-
-
3042822267
-
Cancer and the chemokine network
-
Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4(7): 540-50.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.7
, pp. 540-550
-
-
Balkwill, F.1
-
119
-
-
0033214348
-
CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
-
Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99(1): 23-33.
-
(1999)
Cell
, vol.99
, Issue.1
, pp. 23-33
-
-
Förster, R.1
Schubel, A.2
Breitfeld, D.3
Kremmer, E.4
Renner-Müller, I.5
Wolf, E.6
-
120
-
-
0142166426
-
Chemokines. Agents for the immunotherapy of cancer?
-
Homey B, Müller A, Zlotnik A. Chemokines. Agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2(3): 175-84.
-
(2002)
Nat Rev Immunol
, vol.2
, Issue.3
, pp. 175-184
-
-
Homey, B.1
Müller, A.2
Zlotnik, A.3
-
121
-
-
0034192078
-
Secondary lymphoid tissue chemokine mediates T celldependent antitumor responses in vivo
-
Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, et al. Secondary lymphoid tissue chemokine mediates T celldependent antitumor responses in vivo. J Immunol 2000; 164(9): 4558-63.
-
(2000)
J Immunol
, vol.164
, Issue.9
, pp. 4558-4563
-
-
Sharma, S.1
Stolina, M.2
Luo, J.3
Strieter, R.M.4
Burdick, M.5
Zhu, L.X.6
-
122
-
-
0034663955
-
Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms
-
Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165(4): 1992-2000.
-
(2000)
J Immunol
, vol.165
, Issue.4
, pp. 1992-2000
-
-
Vicari, A.P.1
Ait-Yahia, S.2
Chemin, K.3
Mueller, A.4
Zlotnik, A.5
Caux, C.6
-
123
-
-
0034655163
-
CC chemokine CK b-11/MIP-3 b /ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells
-
Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, et al. CC chemokine CK b-11/MIP-3 b /ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164(8): 3200-06.
-
(2000)
J Immunol
, vol.164
, Issue.8
, pp. 3200-3206
-
-
Braun, S.E.1
Chen, K.2
Foster, R.G.3
Kim, C.H.4
Hromas, R.5
Kaplan, M.H.6
-
125
-
-
0035266293
-
T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy
-
Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Res 2001; 61(5): 2062-70.
-
(2001)
Cancer Res
, vol.61
, Issue.5
, pp. 2062-2070
-
-
Kirk, C.J.1
Hartigan-O'Connor, D.2
Nickoloff, B.J.3
Chamberlain, J.S.4
Giedlin, M.5
Aukerman, L.6
-
126
-
-
0035893749
-
The dynamics of the Tcell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally
-
Kirk CJ, Hartigan-O'Connor D, Mulé JJ. The dynamics of the Tcell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001; 61(24): 8794-802.
-
(2001)
Cancer Res
, vol.61
, Issue.24
, pp. 8794-8802
-
-
Kirk, C.J.1
Hartigan-O'Connor, D.2
Mulé, J.J.3
-
127
-
-
84875302648
-
-
WO2011100460
-
Swartz, M.A., Hubbell, J.A., Tomei, A.A., Shields, J.D., Kourtis, I. Ccr7 ligand delivery and co-delivery in immunotherapy. WO2011100460 (2011).
-
(2011)
Ccr7 ligand delivery and co-delivery in immunotherapy
-
-
Swartz, M.A.1
Hubbell, J.A.2
Tomei, A.A.3
Shields, J.D.4
Kourtis, I.5
-
128
-
-
77957973787
-
Chemokines: Can effector cells be redirected to the site of the tumor?
-
Dubinett SM, Lee JM, Sharma S, Mulé JJ. Chemokines: Can effector cells be redirected to the site of the tumor? Cancer J 2010; 16(4): 325-35.
-
(2010)
Cancer J
, vol.16
, Issue.4
, pp. 325-335
-
-
Dubinett, S.M.1
Lee, J.M.2
Sharma, S.3
Mulé, J.J.4
-
129
-
-
49649091143
-
Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a Phase I trial in nonsmall cell lung cancer
-
Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a Phase I trial in nonsmall cell lung cancer. J Trans Med 2008; 6: 38.
-
(2008)
J Trans Med
, vol.6
, pp. 38
-
-
Baratelli, F.1
Takedatsu, H.2
Hazra, S.3
Peebles, K.4
Luo, J.5
Kurimoto, P.S.6
-
130
-
-
79955754686
-
Novel CCL21-nault vanocapsule intratumoral delivery inhibits lung cancer growth
-
Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, et al. Novel CCL21-nault vanocapsule intratumoral delivery inhibits lung cancer growth. PLoS ONE 2011; 6(5): E18758.
-
(2011)
PLoS ONE
, vol.6
, Issue.5
-
-
Kar, U.K.1
Srivastava, M.K.2
Andersson, A.3
Baratelli, F.4
Huang, M.5
Kickhoefer, V.A.6
-
131
-
-
44349100383
-
Organ selectivity in metastasis: Regulation by chemokines and their receptors
-
Ben-Baruch A. Organ selectivity in metastasis: Regulation by chemokines and their receptors. Clin Exp Metast 2008; 25(4). 345-56.
-
(2008)
Clin Exp Metast
, vol.25
, Issue.4
, pp. 345-356
-
-
Ben-Baruch, A.1
-
132
-
-
0035824083
-
Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
-
Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93(21): 1638-43.
-
(2001)
J Natl Cancer Inst
, vol.93
, Issue.21
, pp. 1638-1643
-
-
Wiley, H.E.1
Gonzalez, E.B.2
Maki, W.3
Wu, M.T.4
Hwang, S.T.5
-
134
-
-
54249152886
-
CCR7 regulates B16 murine melanoma cell tumorigenesis in skin
-
Fang L, Lee VC, Cha E, Zhang H, Hwang ST. CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. J Leukoc Biol 2008; 84(4): 965-72.
-
(2008)
J Leukoc Biol
, vol.84
, Issue.4
, pp. 965-972
-
-
Fang, L.1
Lee, V.C.2
Cha, E.3
Zhang, H.4
Hwang, S.T.5
-
135
-
-
0035282432
-
Involvement of chemokine receptors in breast cancer metastasis
-
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824): 50-6.
-
(2001)
Nature
, vol.410
, Issue.6824
, pp. 50-56
-
-
Müller, A.1
Homey, B.2
Soto, H.3
Ge, N.4
Catron, D.5
Buchanan, M.E.6
-
136
-
-
33846229266
-
Endothelins induce Ccr7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1
-
Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce Ccr7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 2006; 66(24): 11802-7.
-
(2006)
Cancer Res
, vol.66
, Issue.24
, pp. 11802-11807
-
-
Wilson, J.L.1
Burchell, J.2
Grimshaw, M.J.3
-
137
-
-
67649249962
-
Ccr7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia
-
Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, et al. Ccr7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459(7249): 1000-4.
-
(2009)
Nature
, vol.459
, Issue.7249
, pp. 1000-1004
-
-
Buonamici, S.1
Trimarchi, T.2
Ruocco, M.G.3
Reavie, L.4
Cathelin, S.5
Mar, B.G.6
-
138
-
-
33750313449
-
CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells
-
Cappello P, Fraone T, Barberis L, Costa C, Hirsch E, Elia AR, et al. CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells. J Immunol 2006; 177(9): 6143-51.
-
(2006)
J Immunol
, vol.177
, Issue.9
, pp. 6143-6151
-
-
Cappello, P.1
Fraone, T.2
Barberis, L.3
Costa, C.4
Hirsch, E.5
Elia, A.R.6
-
139
-
-
0034254357
-
LEC induces chemotaxis and adhension by interacting with CCR1 and CCR8
-
Howard OMZ, Dong HF, Shirakawa AK, Oppenheim JJ. LEC induces chemotaxis and adhension by interacting with CCR1 and CCR8. Blood 2000; 96(3): 840-5.
-
(2000)
Blood
, vol.96
, Issue.3
, pp. 840-845
-
-
Howard, O.M.Z.1
Dong, H.F.2
Shirakawa, A.K.3
Oppenheim, J.J.4
-
140
-
-
0034653473
-
Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with and impressive recruitment of APCs, lymphocytes, and granulocytes
-
Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW, et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with and impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 2000; 164(6): 3200-6.
-
(2000)
J Immunol
, vol.164
, Issue.6
, pp. 3200-3206
-
-
Giovarelli, M.1
Cappello, P.2
Forni, G.3
Salcedo, T.4
Moore, P.A.5
LeFleur, D.W.6
-
142
-
-
84875336393
-
-
US20040224408
-
Girard, J., Amalric, F., Roussigne, M., Clouaire, T. THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation. US20040224408 (2004).
-
(2004)
THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
-
-
Girard, J.1
Amalric, F.2
Roussigne, M.3
Clouaire, T.4
-
143
-
-
0346995283
-
Complete regression of experimental solid tumors by combination LEC-chTNT-3 immunotherapy and CD25(+) T-cell depletion
-
Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC-chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 2003; 63(23): 8384-92.
-
(2003)
Cancer Res
, vol.63
, Issue.23
, pp. 8384-8392
-
-
Li, J.1
Hu, P.2
Khawli, L.A.3
Epstein, A.L.4
-
144
-
-
77951109790
-
CCL5 as an adjuvant for cancer immunotherapy
-
Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Exp Opin Biol Ther 2010; 10(5): 725-33.
-
(2010)
Exp Opin Biol Ther
, vol.10
, Issue.5
, pp. 725-733
-
-
Lapteva, N.1
Huang, X.F.2
-
146
-
-
47749097074
-
The inflammatory chemokines CCL2 and CCL5 in breast cancer
-
Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267(2): 271-85.
-
(2008)
Cancer Lett
, vol.267
, Issue.2
, pp. 271-285
-
-
Soria, G.1
Ben-Baruch, A.2
-
147
-
-
33745362968
-
T regulatory cells and migration
-
Chen D, Bromberg JS. T regulatory cells and migration. Am J Trans 2006; 6(7): 1518-23.
-
(2006)
Am J Trans
, vol.6
, Issue.7
, pp. 1518-1523
-
-
Chen, D.1
Bromberg, J.S.2
-
148
-
-
47949090079
-
The role of myeloid cells in the promotion of tumour angiogenesis
-
Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8(8): 618-31.
-
(2008)
Nat Rev Cancer
, vol.8
, Issue.8
, pp. 618-631
-
-
Murdoch, C.1
Muthana, M.2
Coffelt, S.B.3
Lewis, C.E.4
-
149
-
-
75149141334
-
CCL2 blockade augments cancer immunotherapy
-
Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010; 70(1): 109-18.
-
(2010)
Cancer Res
, vol.70
, Issue.1
, pp. 109-118
-
-
Fridlender, Z.G.1
Buchlis, G.2
Kapoor, V.3
Cheng, G.4
Sun, J.5
Singhal, S.6
-
150
-
-
77951631347
-
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth
-
Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010; 102(8): 522-8.
-
(2010)
J Natl Cancer Inst
, vol.102
, Issue.8
, pp. 522-528
-
-
Zhang, J.1
Lu, Y.2
Pienta, K.J.3
-
151
-
-
15744364923
-
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12
-
Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 2005; 12(4): 359-68.
-
(2005)
Cancer Gene Ther
, vol.12
, Issue.4
, pp. 359-368
-
-
Parker, J.N.1
Meleth, S.2
Hughes, K.B.3
Gillespie, G.Y.4
Whitley, R.J.5
Markert, J.M.6
-
152
-
-
0035102199
-
Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor
-
Nagai M, Masuzawa T. Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor. Int Immunopharmacol 2001; 1(4): 657-64.
-
(2001)
Int Immunopharmacol
, vol.1
, Issue.4
, pp. 657-664
-
-
Nagai, M.1
Masuzawa, T.2
-
153
-
-
0029103127
-
Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration
-
Hirose K, Hakozaki M, Nyunoya Y, Kobayashi Y, Matsushita K, Takenouchi T, et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 1995; 72(3): 708-14.
-
(1995)
Br J Cancer
, vol.72
, Issue.3
, pp. 708-714
-
-
Hirose, K.1
Hakozaki, M.2
Nyunoya, Y.3
Kobayashi, Y.4
Matsushita, K.5
Takenouchi, T.6
-
154
-
-
77953610370
-
Therapeutic effect of MIP-1a-recruited dendritic cells on preestablished solid and metastatic tumors
-
Cao Q, Jin Y, Jin M, He S, Gu Q, He S, et al. Therapeutic effect of MIP-1a-recruited dendritic cells on preestablished solid and metastatic tumors. Cancer Lett 2010; 295(1): 17-26.
-
(2010)
Cancer Lett
, vol.295
, Issue.1
, pp. 17-26
-
-
Cao, Q.1
Jin, Y.2
Jin, M.3
He, S.4
Gu, Q.5
He, S.6
-
155
-
-
70449706176
-
Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma
-
Aravindaram K, Yu HH, Lan CW, Wang PH, Chen YH, Chen HM, et al. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma. Gene Ther 2009; 16(11): 1329-39.
-
(2009)
Gene Ther
, vol.16
, Issue.11
, pp. 1329-1339
-
-
Aravindaram, K.1
Yu, H.H.2
Lan, C.W.3
Wang, P.H.4
Chen, Y.H.5
Chen, H.M.6
-
156
-
-
45849101661
-
TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model
-
Inoue H, Iga M, Xin M, Asahi S, Nakamura T, Kurita R, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother 2008; 57(9): 1399-411.
-
(2008)
Cancer Immunol Immunother
, vol.57
, Issue.9
, pp. 1399-1411
-
-
Inoue, H.1
Iga, M.2
Xin, M.3
Asahi, S.4
Nakamura, T.5
Kurita, R.6
-
157
-
-
58549085171
-
Vaccination with combination of Fit3L and RANTES in a DNA primeprotein boost regimen elicits strong cell-mediated immunity and antitumor effect
-
Song S, Liu C, Wang J, Zhang Y, You H, Wang Y, et al. Vaccination with combination of Fit3L and RANTES in a DNA primeprotein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine 2009; 27(7): 1111-8.
-
(2009)
Vaccine
, vol.27
, Issue.7
, pp. 1111-1118
-
-
Song, S.1
Liu, C.2
Wang, J.3
Zhang, Y.4
You, H.5
Wang, Y.6
-
159
-
-
77957157551
-
The multiple faces of CXCL12 (SDF-1a) in the regulation of immunity during health and disease
-
Karin N. The multiple faces of CXCL12 (SDF-1a) in the regulation of immunity during health and disease. J Leukoc Biol 2010; 88(3): 463-73.
-
(2010)
J Leukoc Biol
, vol.88
, Issue.3
, pp. 463-473
-
-
Karin, N.1
-
160
-
-
78449300594
-
CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
-
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metast Rev 2010; 29(4): 709-22.
-
(2010)
Cancer Metast Rev
, vol.29
, Issue.4
, pp. 709-722
-
-
Sun, X.1
Cheng, G.2
Hao, M.3
Zheng, J.4
Zhou, X.5
Zhang, J.6
-
161
-
-
77953090345
-
CXCL12 (SDF-1)/ CXCR4 pathway in cancer
-
Teicher BA, Fricker SP. CXCL12 (SDF-1)/ CXCR4 pathway in cancer. Clin Cancer Res 2010; 16(11): 2927-31.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.11
, pp. 2927-2931
-
-
Teicher, B.A.1
Fricker, S.P.2
-
162
-
-
0035658072
-
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
-
Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7(12): 1339-46.
-
(2001)
Nat Med
, vol.7
, Issue.12
, pp. 1339-1346
-
-
Zou, W.1
McHelon, V.2
Coulomb-L'Hermin, A.3
Borvak, J.4
Nome, F.5
Isaeva, T.6
-
164
-
-
19944433608
-
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo
-
Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20(2): 318-29.
-
(2005)
J Bone Miner Res
, vol.20
, Issue.2
, pp. 318-329
-
-
Sun, Y.X.1
Schneider, A.2
Jung, Y.3
Wang, J.4
Dai, J.5
Wang, J.6
-
165
-
-
13444265875
-
Silencing of CXCR4 blocks breast cancer metastasis
-
Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005; 65(3): 967-71.
-
(2005)
Cancer Res
, vol.65
, Issue.3
, pp. 967-971
-
-
Liang, Z.1
Yoon, Y.2
Votaw, J.3
Goodman, M.M.4
Williams, L.5
Shim, H.6
-
166
-
-
35648945337
-
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature
-
Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007; 104(40): 15735-40.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.40
, pp. 15735-15740
-
-
Miao, Z.1
Luker, K.E.2
Summers, B.C.3
Berahovich, R.4
Bhojani, M.S.5
Rehemtulla, A.6
-
167
-
-
70350317612
-
CXCL12, CXCR4 and CXCR7 expression in brain metastases
-
Salmaggi A, Maderna E, Calatozzolo C, Gaviani P, Canazza A, Milanesi I, et al. CXCL12, CXCR4 and CXCR7 expression in brain metastases. Cancer Biol Ther 2009; 8(17): 1608-14.
-
(2009)
Cancer Biol Ther
, vol.8
, Issue.17
, pp. 1608-1614
-
-
Salmaggi, A.1
Maderna, E.2
Calatozzolo, C.3
Gaviani, P.4
Canazza, A.5
Milanesi, I.6
-
168
-
-
33750455077
-
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
-
Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 2006; 5(10): 2592-9.
-
(2006)
Mol Cancer Ther
, vol.5
, Issue.10
, pp. 2592-2599
-
-
Lee, C.H.1
Kakinuma, T.2
Wang, J.3
Zhang, H.4
Palmer, D.C.5
Restifo, N.P.6
-
170
-
-
84875319398
-
-
WO2007074871
-
Fujii, N., Hamachi, I., Ojida, A., Tamamura, H., Nakashima, H. Novel CXCR4 antagonist and use thereof. WO2007074871 (2007).
-
(2007)
Novel CXCR4 antagonist and use thereof
-
-
Fujii, N.1
Hamachi, I.2
Ojida, A.3
Tamamura, H.4
Nakashima, H.5
-
172
-
-
84867551927
-
-
WO2010054006
-
Chen, X., Fan, P., Gleason, M.M., Jaen, J.C., Li, L., Mcmahon, J.P., Powers, J., Zeng, Y., Zhang, P. Modulators of CXCR7. WO2010054006 (2010).
-
(2010)
Modulators of CXCR7
-
-
Chen, X.1
Fan, P.2
Gleason, M.M.3
Jaen, J.C.4
Li, L.5
McMahon, J.P.6
Powers, J.7
Zeng, Y.8
Zhang, P.9
|